Finepoint Capital LP Has $20.85 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Finepoint Capital LP raised its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 2.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 650,852 shares of the company’s stock after purchasing an additional 12,500 shares during the period. SpringWorks Therapeutics makes up approximately 1.5% of Finepoint Capital LP’s holdings, making the stock its 7th biggest position. Finepoint Capital LP owned 0.88% of SpringWorks Therapeutics worth $20,853,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of SWTX. FMR LLC increased its position in shares of SpringWorks Therapeutics by 0.3% during the third quarter. FMR LLC now owns 11,140,946 shares of the company’s stock valued at $356,956,000 after purchasing an additional 28,555 shares during the period. Vanguard Group Inc. boosted its stake in SpringWorks Therapeutics by 8.2% during the first quarter. Vanguard Group Inc. now owns 6,529,325 shares of the company’s stock worth $321,373,000 after buying an additional 492,783 shares in the last quarter. Maverick Capital Ltd. raised its stake in shares of SpringWorks Therapeutics by 36.3% in the 2nd quarter. Maverick Capital Ltd. now owns 2,600,524 shares of the company’s stock valued at $97,962,000 after buying an additional 691,894 shares in the last quarter. Fiera Capital Corp raised its stake in shares of SpringWorks Therapeutics by 41.4% in the 2nd quarter. Fiera Capital Corp now owns 1,297,302 shares of the company’s stock valued at $48,869,000 after buying an additional 380,027 shares in the last quarter. Finally, Duquesne Family Office LLC bought a new position in shares of SpringWorks Therapeutics during the 2nd quarter worth about $38,475,000.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SWTX. Wedbush reissued an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a research report on Monday, November 18th. JPMorgan Chase & Co. raised their target price on SpringWorks Therapeutics from $64.00 to $68.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Evercore ISI assumed coverage on SpringWorks Therapeutics in a research report on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, HC Wainwright cut their price objective on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a report on Tuesday, November 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SpringWorks Therapeutics presently has an average rating of “Buy” and an average target price of $67.00.

SpringWorks Therapeutics Stock Performance

SpringWorks Therapeutics stock opened at $39.39 on Tuesday. SpringWorks Therapeutics, Inc. has a 52 week low of $20.19 and a 52 week high of $53.92. The firm has a market cap of $2.93 billion, a P/E ratio of -10.15 and a beta of 0.79. The business’s fifty day moving average is $32.68 and its two-hundred day moving average is $36.71.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.03. The firm had revenue of $49.10 million for the quarter, compared to analyst estimates of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The company’s revenue was up 4810.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.27) EPS. On average, equities research analysts predict that SpringWorks Therapeutics, Inc. will post -3.12 earnings per share for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.